Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: larry who wrote (90914)	1/13/2000 11:48:00 PM
From: Derrick P.	Respond to of 164684

larry, Well, what do you think of this, from Mark Fowler's new hot pick Crgn: CuraGen Corporation is pioneering the systematic application of genomics to accelerate the discovery and development of therapeutic and agricultural products. CuraGen's fully-integrated genomics technologies, processes and information systems are designed to rapidly generate comprehensive information about gene sequences, gene expression, biological pathways and the potential drugs that affect these pathways, each on a scale not previously undertaken. The Company's drug discovery platform has three primary systems: the SeqCalling system for the generation of coding sequences for expressed genes within a sample, including sequences for rarely expressed and novel genes; the GeneCalling system for comprehensive gene expression analysis and gene discovery; and the PathCalling system for discovery of the roles of genes and the proteins they encode in biological pathways. biz.yahoo.com It sure looks like they are using genomic data to develop new drugs. And look at the stock, up from $5 to $95 this year. Someone sure thinks that this is the $hit. Of course this is in reference to CRA and their genomic data. Hmmmm?